Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
Revenue from operations up 26% to Rs. 768 crores
The company shall be engaged in the business of manufacturing of pharmaceutical, bio-pharmaceutical and biological products of any kind
A special purpose vehicle (SPV) formed by O2 Energy SG Pte Ltd, for generation and supply of renewable power
Company raises the annual revenue guidance from mid-teens to high teens
Subscribe To Our Newsletter & Stay Updated
